Different dermatologic diseases management using oral Janus kinase inhibitor tofacitinib: A series of 5 cases

In recent years tofacitinib shows giant potential in the field of dermatology, and here we report five individuals with positive responses to tofacitinib treatment in different dermatologic diseases.Supplemental Fig1. Clinical improvement in nail lichen planus with tofacitinib. A, An involvement of all fingernails and toenails with diffuse longitudinal ridging, fissuring of the nail plate, as well as distal splitting, some nails also exhibited pterygium. B, Significant improvement of most nails after 3 months of tofacitinib treatment.Supplemental Fig2. Clinical improvement in pemphigoid nodularis with tofacitinib. A, Densely distributed nodules with erosions, crusts, and scales on the patient’s legs. B, Response to tofacitinib 5 mg twice daily.Supplemental Fig3. Clinical improvement in erythema multiforme with tofacitinib. A-C, Multiple pink to violaceous macules or targetoid, geographic plaques, and pigmentation remaining after the lesion subsided. Lesion size ranged from 0.2-2cm and lesions were distributed on bilateral hands (A), elbows (B), and ankles (C). D-F, Complete resolution of skin lesions after treatment with tofacitinib at week 2. Supplemental Fig4. Clinical improvement in pityriasis rosea with tofacitinib. A, Multiple erythematous oval patches and plaques with a peripheral collarette scaling and several blisters on the patient’s trunk. B, After therapy with tofacitinib 5 mg twice a day.Supplemental Fig5. Clinical improvement in gefitinib drug-related skin adverse reaction with tofacitinib. A, widespread erythematous papules and several small pustules on the face. B, After 2 weeks of tofacitinib treatment.